Results 121 to 130 of about 6,146 (182)

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1304-1314, February 2026.
Abstract Aim PIONEER REAL Saudi Arabia investigated real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults with type 2 diabetes (T2D). Materials and Methods This was a 34‐ to 44‐week multicentre, prospective, open‐label study in adults with T2D, who were treatment‐naive to injectable glucose‐lowering medication ...
Hussein ElBadawi, Nader Albalkhi, Ibrahim Al Kadhim, Ahmed Elsadig, Dimitrios Baltzis, Mohamed Hassan Hatahet, Mahmoud Ismail, Said Khader, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Ahmed Shalaby, Mohammed Almehthel   +11 more
wiley   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source

Analisi di Impatto Sul Budget di Empagliflozin Nel Trattamento Dei Pazienti Con Diabete di tipo 2 e Malattia Cardiovascolare Accertata [PDF]

, 2017
Sergio Iannazzo, Aldo P. Maggioni, Edoardo Mannucci   +2 more
openalex   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

The biology of PKM2 in the metabolism and senescence in diabetic kidney disease

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 197-204, February 2026.
ABSTRACT Diabetic kidney disease (DKD) is one of the most common causes of chronic kidney disease that leads to end‐stage kidney disease, and its progression is closely linked to metabolic stress within renal tubular cells. Under long‐term hyperglycemia, cells shift their glucose metabolism from normal oxidative phosphorylation toward glycolysis.
Md. Imrul Kayes, Keizo Kanasaki
wiley   +1 more source

Review for "Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose‐lowering therapy?"

, 2019
Ghadeer Dawas
openalex   +1 more source

Empagliflozin does not prevent progression of Dent's disease type 1 in a mouse model

Experimental Physiology, Volume 111, Issue 2, Page 517-526, 1 February 2026.
Abstract Dent's disease is a rare inherited renal disorder characterized by generalized proximal tubule dysfunction with low molecular weight proteinuria, hypercalciuria, and urinary loss of other solutes. The disease is progressive and leads to chronic kidney disease.
Elise de Combiens, Nadia Frachon, Yohan Bignon, Marc Fila, Clément Brossard, Perrine Frère, Stéphane Lourdel   +6 more
wiley   +1 more source

Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1537-1540, February 2026.
Amrit Pathak, M. Belinda Hardin, Manon Girard, Michael J. Davies, William B. Horton   +4 more
wiley   +1 more source

The SGLT-2 Inhibitor Empagliflozin Improves Myocardial Strain, Reduces Cardiac Fibrosis and Pro-Inflammatory Cytokines in Non-Diabetic Mice Treated With Doxorubicin [PDF]

, 2020
Vincenzo Quagliariello, Michelino De Laurentiis, Domenica Rea, Antônio Barbieri, M. Monti, Antonietta Caronna, Annamaria Bonelli, Gerardo Botti, Nicola Maurea   +8 more
openalex   +1 more source

Review for "Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects"

, 2021
Thomas Hach
openalex   +1 more source